Publication:
Pushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review

Simple item page
dc.contributor.authorBarber, Benjamin
dc.contributor.authorDiestre, Luis
dc.contributor.rorhttps://ror.org/02jjdwm75
dc.date.accessioned2024-07-02T16:11:29Z
dc.date.available2024-07-02T16:11:29Z
dc.date.issued2019-04-02
dc.description.abstractWe argue firms implementing political activities face a fundamental trade-off between the content and the speed of public officials’ decisions. We show evidence of this trade-off looking at FDA drug approvals: lobbying for broader drugs leads to longer revisions, whereas lobbying to speed up the review process leads to narrower drugs. How do firms respond to this trade-off? We argue firms’ lobbying strategies depend upon the level of IP protection behind their drugs. We predict that firms with high levels of IP protection will lobby for drug scope, whereas firms with low levels of IP protection will lobby for revision speed. We find support for our theory in a sample of 540 new drug applications to the FDA from 1998 to 2015.
dc.formatapplication/pdf
dc.identifier.citationBarber IV, B., & Diestre, L. (2019). Pushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review. Strategic Management Journal, 40(8), 1194-1218.
dc.identifier.doihttps://doi.org/10.1002/smj.3021
dc.identifier.issn0143-2095
dc.identifier.urihttps://hdl.handle.net/20.500.14417/2890
dc.issue.number8
dc.journal.titleStrategic Management Journal
dc.language.isoeng
dc.page.final1218
dc.page.initial1194
dc.page.total1194-1218
dc.publisherWiley
dc.relation.entityIE University
dc.rightsAttribution Non-Commercial No-Derivatives 4,0 International
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.subject.keywordCorporate political activities
dc.subject.keywordLobbying
dc.subject.keywordInnovation
dc.subject.keywordNew product development
dc.subject.keywordPharmaceutical industry
dc.subject.otherCorporate political activities;Lobbying;Innovation;New product development;Pharmaceutical industry
dc.titlePushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review
dc.typeinfo:eu-repo/semantics/article
dc.version.typeinfo:eu-repo/semantics/acceptedVersion
dc.volume.number40
dspace.entity.typePublication
relation.isAuthorOfPublicationee50c52d-1b33-4b98-bd82-80590a37dd42
relation.isAuthorOfPublication9c2e697b-9b71-43c9-9c90-6d207e4fb494
relation.isAuthorOfPublication.latestForDiscoveryee50c52d-1b33-4b98-bd82-80590a37dd42
relation.isAuthorOfPublication.latestForDiscoveryee50c52d-1b33-4b98-bd82-80590a37dd42
relation.isAuthorOfPublication.latestForDiscovery9c2e697b-9b71-43c9-9c90-6d207e4fb494
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
10631532.pdf
Size:
861.5 KB
Format:
Adobe Portable Document Format
Download
Collections
Research Articles